Correction to "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma".

Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, et al. Br J Haematol. 2021;194(4):690-700. On page 3 of the "Bridging Therapy Regimens" section of the Supplementary Appendix methods, the dose of rituximab that was administered in combination with bendamastine as optional bridging therapy was incorrectly reported as 275 mg/m2. The proper dose of rituximab was 375 mg/m2, and the text should have read: "Bendamustine (90 mg/m2 on days 1 and 2) in combination with rituximab (375 mg/m2 on day 1)." We apologize for this error.